The PRODIGY (formerly CKS) topic on chronic obstructive pulmonary disease (COPD) has been updated and is available from the link below. It now includes the new NICE recommendations from its COPD Quality Standard document for people receiving long-term oxygen therapy. New evidence from a large systematic review and meta-analysis has also been incorporated to include updated evidence which found that compared with placebo, Spiriva Respimat® 5 micrograms/day was associated with a statistically significant increased risk of mortality.